PRTA tech validated by big BMS collaboration • BMS is part owner of PRTA BMS & PRTA collaboration highlights: 3/20/18 CELG & PRTA enter...

Conclusion: Mixed positive Positives: Efficacy ACU193 appears to reduce plaque @ highest dose levels AFAIK 1st time plaque reduction shown by binding oligomers ABOS concludes plaque reduction similar to “approved BA Abs” Plaque clearance data only out to ~3 months so hard to know Donanemab is probably best at clearing plaque ( See comparative table ) Serum pK looks good for monthly dosing Assay Csf target engagement assay Looks like it works well enough to help clin dev Impre

But, which is the best? • Some anti-beta amyloids (ABs) made it ⇒ thru pos Ph3 ⇒ 1 full FDA approval But lots of ABs have died in...